Growth Metrics

Quest Diagnostics (DGX) Net Income towards Common Stockholders (2016 - 2025)

Quest Diagnostics' Net Income towards Common Stockholders history spans 17 years, with the latest figure at $213.0 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 8.67% year-over-year to $213.0 million; the TTM value through Dec 2025 reached $861.0 million, up 13.44%, while the annual FY2025 figure was $968.0 million, 11.65% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $213.0 million at Quest Diagnostics, roughly flat from $214.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $721.0 million in Q2 2021 and bottomed at $76.0 million in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is $205.5 million (2022), against an average of $250.5 million.
  • The largest annual shift saw Net Income towards Common Stockholders skyrocketed 1542.0% in 2021 before it crashed 71.29% in 2022.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $227.0 million in 2021, then tumbled by 66.52% to $76.0 million in 2022, then skyrocketed by 113.16% to $162.0 million in 2023, then increased by 20.99% to $196.0 million in 2024, then grew by 8.67% to $213.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Net Income towards Common Stockholders are $213.0 million (Q4 2025), $214.0 million (Q3 2025), and $250.0 million (Q2 2025).